IMMUNOHISTOCHEMISTRY, CDX-2

The IHC – CDX2 (Caudal Type Homeobox 2) test is an immunohistochemistry-based diagnostic assay used to detect CDX2 protein expression in tissue samples. CDX2 is a nuclear transcription factor that plays a critical role in the development and maintenance of intestinal epithelial cells. Because of its strong association with intestinal tissue, CDX2 is widely used as a marker for gastrointestinal tract tumors.

This test is particularly valuable in diagnosing colorectal adenocarcinoma and determining whether a metastatic tumor originated from the gastrointestinal tract. CDX2 staining helps pathologists identify intestinal differentiation and accurately classify tumors, especially when the primary site of cancer is uncertain.

Benefits of the Test

• Helps diagnose colorectal cancer
• Assists in identifying gastrointestinal tumor origin
• Supports differentiation of metastatic tumors
• Improves tumor classification accuracy
• Helps guide oncology treatment planning

Why Doctors Recommend This Test

Doctors recommend the IHC CDX2 test when there is suspicion of colorectal cancer, gastrointestinal tumors, or metastatic cancer of unknown origin. It is commonly used in:

• Diagnosis of colorectal adenocarcinoma
• Evaluation of gastrointestinal tract tumors
• Investigation of metastatic cancer
• Tumor origin identification studies
• Oncology biopsy interpretation

CDX2 is often used together with markers such as CK20, CK7, SATB2, MUC2, and Villin to improve diagnostic accuracy and determine tumor origin.

Preparation Before Test

No special preparation is required from the patient. Important considerations include:

• The test is performed on a biopsy or surgical tissue sample
• No fasting or medication restrictions are needed
• Clinical history, imaging studies, and previous pathology reports may assist interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

• Patients with suspected colorectal cancer
• Individuals with gastrointestinal tumors
• Cases of metastatic cancer with unknown primary origin
• Patients undergoing tumor biopsy evaluation
• Oncology patients requiring immunohistochemistry profiling

The IHC CDX2 test is an important diagnostic tool in gastrointestinal pathology and oncology. By identifying intestinal epithelial differentiation, it helps clinicians accurately diagnose colorectal and gastrointestinal cancers and develop effective treatment strategies.